Cancer Systems Biology Approaches For Developing Treatment Strategies Against B Cell Lymphoma by Du, Wei
  
CANCER SYSTEMS BIOLOGY APPROACHES FOR DEVELOPING 
TREATMENT STRATEGIES AGAINST B CELL LYMPHOMA 
 
 
 
 
 
 
A Dissertation 
Presented to Faculty of the Weill Cornell Graduate School 
 of Medical Sciences 
in Partial Fulfillment of the Requirements for the Degree of  
Doctor of Philosophy 
 
 
 
 
 
by 
Wei Du 
August 2018 
  
 
 
 
 
 
 
 
Ó2018 Wei Du 
 
 
 
 
 
 
 
 
	CANCER SYSTEMS BIOLOGY APPROACHES FOR DEVELOPING 
TREATMENT STRATEGIES AGAINST B CELL LYMPHOMA 
 
Wei Du, Ph.D. 
Cornell University 2018 
 
The transformation from normal cells to cancer cells and the maintenance of the 
malignant state and phenotypes are associated with genetic and epigenetic deregulations, 
altered cellular signaling responses and aberrant interactions with the microenvironment. 
This intrinsic complexity of cancer biology calls for novel systems level approaches for 
understanding tumorigenesis and for developing effective therapeutic strategies. 
Computational approaches in cancer systems biology embraces this complexity and 
studies cancer from a systems point of view. In this thesis, we combine various cancer 
systems biology methodologies including mathematical modeling, statistics and 
machine learning approaches to study B cell lymphoma biology from two different 
angles and bring about guidance to treatment strategies. In the first chapter, we present 
a novel kinetic modeling based computational framework for optimizing combinatorial 
therapies against chronic active B cell receptor(BCR) signaling in B cell lymphoma. In 
the second chapter, we describe a Bayesian classifier that’s able to stratify cell of origin 
subtypes of diffuse large B cell lymphoma based on RNA-Seq data, which is predictive 
of clinical outcomes. We discuss how above computational analysis provides novel 
methodology for advising therapeutic strategies.   
iii	
	
 
BIOGRAPHICAL SKETCH 
 
Wei Du was born in Beijing, the capital of China. After completing high school 
education at Beijing No.4 High School in 2008, she entered Peking University majoring 
in physics and graduated in 2012. Afterwards she started her doctoral training at 
Physiology, Biophysics and Systems Biology program in Weill Cornell Graduate 
School of Medical Sciences, supervised by Dr. Olivier Elemento. Her major work 
during graduate research is the development of a computational model of the B cell 
receptor signaling pathway which can be used to predict effective and synergistic drug 
combinations. Besides her research, she entertains as a singer-song writer and has 
completed an album of 11 original songs.  
 
 
 
 
 
 
 
 
 
 
 
iv	
	
ACKNOWLEDGEMENTS 
 
First of all, I would like to express my deepest gratitude to my advisor, Dr. Olivier 
Elemento, for his continuous support of my graduate research and excellent mentorship. 
He not only offered brilliant scientific guidance but also provided the greatest emotional 
support that helped me finish my Ph.D. study. It would not be possible to complete this 
work without his generous help and tremendous patience.  
 
I would also like to thank my committee members: Dr. John Chodera, Dr. Ari Melnick 
and Dr. Leandro Cerchietti, who offered very valuable insights on my projects over the 
years.  
 
Thank to all members of Elemento lab for their constructive comments and suggestions 
on my projects over the years. Special thank to Heng Pan for many helpful discussions.  
 
Thank to my good friends at PKU, Zhen Bi, Quan Zhou, Lixin Sun, Xin Liang, Yunkun 
Xie, Junwu Huang who offered tremendous emotional support during my Ph.D. training.  
 
Last but not least, I would like to thank my parents who are always loving and supportive.   
 
 
 
 
v	
	
TABLE OF CONTENTS 
 
ABSTRACT ...………………………………………………………………………… i 
BIOGRAPHICAL SKETCH ...………………………………………………………  iii 
ACKNOWLEDGEMENTS …………………………………………………………. iv 
TABLE OF CONTENTS ……………………………………………………………. v 
LIST OF FIGURES ………………………………………………………………… viii 
LIST OF TABLES …………………………………………………………………..  x 
 
1. CHAPTER ONE: INTRODUCTION 
1.1 Oncogenic signaling in cancer and targeted therapy ………………………… 1 
1.2 Complexity of signaling networks limits the effectiveness of single agent 
targeted therapy and call for usage of combination 
therapy ……………………………………………………………………….. 1 
1.3 Computational models of signaling networks for predicting effective 
combination therapy …………………………………………………………. 2 
1.4 Overview of diffuse large B cell lymphoma and stratification of its 
subtypes ……………………………………………………………………… 3 
1.5 Deregulation of B cell receptor signaling and pathogenesis of activated B cell-
like subtype of diffuse large B cell lymphoma ………………………………. 4 
1.6 Construction of computational model of the BCR signaling network and 
prediction of effective combination therapy …………………………………. 5 
      List of Publications ………………………………………………………………. 8 
vi	
	
2. CHAPTER TWO:  EFFECTIVE COMBINATION THEAPIES FOR B CELL 
LYMPHOMA PREDICTED BY A VIRTUAL DISEASE MODEL 
2.1 Kinetic modeling of BCR signaling network reproduces normal BCR signaling 
in silico………………………………………………………………………. 10 
2.2 Combining BCR signaling model with a tumor growth model predicted cell 
viability response upon single and combinatorial drug treatments in a BCR 
signaling-dependent ABC DLBCL cell line ………………………………… 27 
2.3 Crosstalk between PI3K and NFkB pathway mediates efficacy of PI3K 
inhibition in TMD8 ……………………………………………………………… 34 
2.4 Computational optimization of targeted therapy against chronic active BCR 
signaling …………………………………………………………………………. 34 
2.5 Comparison of the kinetic model to a simpler Boolean network model …….. 41 
 
 
3. CHAPTER THREE: PREDICTING ABC VS. GCB SUBTYPES OF DIFFUSE 
LARGE B CELL LYMPHOMA FROM RNA-SEQ DATA 
3.1 Z score normalization and Bayesian classifier for ABC/GCB DLBCL 
classification ………………………………………………………………...  45 
3.2 Testing the ABC/GCB classifier within the pre-labeled microarray dataset ... 49 
3.3 Applying ABC/GCB classifier to clinic cohort and comparison with IHC label 
and Lymph2Cx 20 gene signature profiling ……………………………….... 53 
3.4 RNA-Seq based ABC/GCB classifier outperformed IHC label in stratifying two 
subgroups with distinct probability of survival ……………………………… 59 
vii	
	
 
4. CHAPTER FOUR: DISCUSSION ……………………………………………… 62 
 
 
REFERENCES ……………………………………………………………………...  68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii	
	
LIST OF FIGURES 
Figure 1.1 Outline of the approach taken in the present study………………………  6 
Figure 2.1 The central BCR signaling network constructed from literature………… 11 
Figure 2.2 Equations in kinetic model of BCR signaling network …………………. 17 
Figure 2.3 Simulated normal BCR signaling ……………………………………….. 21 
Figure 2.4 Residual sum of square as a function of signal-to-noise ratio ……………22 
Figure 2.5 Parameter sensitivity analysis …………………………………………… 23 
Figure 2.6 Comparison between literature-retrieved parameter values with simulation-
estimated parameter ranges …………………………………………………………. 26 
Figure 2.7 Empirical cumulative distribution of the number of parameters that would 
fall within simulation-estimated parameter ranges by chance derived by shuffling the 
literature-retrieved parameters 10,000 times ………………………………………… 27 
Figure 2.8 Training and prediction of single drug viability response in ABC DLBCL 
cell line TMD8 ………………………………………………………………………. 33 
Figure 2.9 Combinatorial drug viability responses of BTK inhibitor Ibrutinib in 
combination with additional inhibitors targeting BCR network intermediates were 
predicted and compared with experimental data …………………………………….. 33 
Figure 2.10 Computational optimization of treatment strategy against chronic active 
BCR signaling ………………………………………………………………………. 36 
Figure 2.11 Prediction and validation of synergistic and antagonistic drug 
combinations ………………………………………………………………………… 39 
ix	
	
Figure 2.12  Simplified BCR signaling network consisting of only the 11 targetable 
nodes together with signaling pathway end points and a node representing cell 
viability………………………………………………………………………………. 42 
Figure 2.13 Attractor landscape of Boolean network model ........................................ 43  
Figure 2.14 Viability response of drug combination BTK+MEK and BTK+RAF in 
TMD8 ……………………………………………………………………………….. 44 
Figure 3.1 Diagram of the approach taken in the study ……………………………… 47 
Figure 3.2 Classification on microarray dataset and comparison to pre-existing 
labels ………………………………………………………………………………… 50 
Figure 3.3 Classification of RNA-Seq data and comparison to IHC labels ………… 54 
Figure 3.4 Hierarchical clustering based on Lymph2Cx 20 gene signature profiling and 
comparison between genes in Bayesian classifier and in Lymph2Cx 20 gene 
signature …………………………………………………………………………….. 56 
Figure 3.5 Kaplan-Meier plots of patient survival in subgroups defined by IHC labels 
or RNA-Seq classification ………………………………………………………….. 60 
 
 
 
 
 
 
 
 
x	
	
 
LIST OF TABLES 
Table 2.1 Table of total protein concentration in the kinetic model ………………..... 19 
Table 2.2 Kinetic parameter bounds ………………………………………………… 20 
Table 2.3 Inhibitors against BCR signaling network ………………………………... 30 
 
 
 
 
 
 
 
 
 
1	
	
CHAPTER ONE  INTRODUCTION 
 
1.1 Oncogenic signaling in cancer and targeted therapy 
 
The activation of intracellular signaling pathways in response to environmental stimulus 
leads to important cell decisions such as proliferation. The amplitude and duration of 
pathway activation are precisely and robustly controlled by complex regulatory loops 
to maintain cellular homeostasis. In cancer, activating mutations or deletion of signaling 
repressors frequently result in sustained and exaggerated pathway activation that drives 
uncontrolled tumor survival and proliferation. Targeted therapies that use small 
molecule inhibitors to repress specific signaling pathway members, e.g. kinases, can 
directly block oncogenic pathway activation and lead to tumor cell death. These targeted 
therapies are expected to provide improved efficacy and reduced toxicity compared to 
chemotherapy.    
 
1.2 Complexity of signaling networks limits the effectiveness of single agent targeted 
therapy and call for usage of combination therapy 
 
Despite the expectation of improved efficacy, clinical application of targeted therapy is 
facing several challenges such as low response rate and frequently acquired drug 
resistance. The limited efficacy of single agent targeted therapy is at least partially due 
to pathway crosstalks and compensatory circuits within signaling networks targeted by 
these agents(1). Crosstalks and compensatory circuits allow signals to bypass drug 
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inhibition and reactivate downstream effectors. By simultaneously repressing multiple 
nodes in a signaling network, combination therapy has the potential to completely 
extinguish oncogenic signaling and induce more potent and durable treatment response. 
Thus, novel drug combinations where two or more drugs work cooperatively to suppress 
corrupted signaling networks need to be identified to achieve maximum therapeutic 
efficacy. The complexity of signaling networks makes it difficult to simply guess which 
combinations will be effective and synergistic and which ones will not. Moreover, given 
the large number of possible drug combinations against complex signaling networks, 
comprehensive experimental screening – including exploration of multiple dosages – 
is not practically feasible.  Besides, results acquired from such screening may be specific 
to the cell line tested, thus lacking general applicability to highly variable primary 
tumors found in patients.  
 
1.3 Computational models of signaling networks for predicting effective combination 
therapy 
 
Computational models of signaling networks that can accurately reconstruct signaling 
dynamics in silico may represent a useful alternative to experimental screening and trial-
and-error experimental investigation. Once proven reliable, these models can be used to 
exhaustively test the efficacy of a large number of single drug and drug combinations 
by quantifying signaling output under corresponding network perturbations. Even 
though computational modeling has been widely used to study the dynamics of signaling 
network in the past decades, the development of cancer signaling models and its 
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application to predicting effective combinatorial therapies is still lacking. In the second 
chapter, we demonstrate the feasibility of this approach using chronic activation of B 
cell receptor (BCR) signaling in diffuse large B cell lymphoma (DLBCL) as a model 
system. We adopted a systems biology approach and established a computational 
framework to optimize anti-DLBCL combinatorial therapy in silico. The proposed 
approach is broadly applicable and can be used for other malignancies driven by 
aberrantly active signaling pathways. 
 
1.4 Overview of diffuse large B cell lymphoma and stratification of its subtypes 
 
Diffuse large B cell lymphoma is the most prevalent subtype of non-Hodgkin’s 
lymphoma, with patients responding variably to chemotherapy(2). Using gene 
expression profiling, two distinct subtypes of DLBCL were identified, which associate 
with different clinical outcome(3). One subtype, termed activated B cell like(ABC) 
DLBCL, shows gene expression signature of antigen-activated blood B cell. Another 
subtype, termed germinal center B cell like (GCB) DLBCL, express genes characteristic 
of germinal center B cells. It was shown that ABC DLBCL was associated with poorer 
survival upon chemotherapy. A gene expression based classifier was later developed to 
stratify the two subtypes of DLBCL in microarray datasets(4). 
 
Even though a gene expression based classifier was developed, currently no software is 
available for implementing it.  Secondly, while such classifier was tested on microarray 
datasets, it is unclear how to apply the classifier to RNA-Seq profiles. In the third 
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chapter we present a simple R package adapting the original Bayesian classifier to 
classify ABC vs. GCB DLBCL. Prior to classification we implemented z score 
normalization of both training and to-be-classified data, which allowed us to classify 
profiles from different platforms such as microarray and RNA-Seq. We successfully 
applied this method to a DLBCL RNA-Seq dataset consisting of 68 patients, where the 
ABC/GCB classification significantly stratified two subgroups with distinct probability 
of survival. Moreover, we show that RNA-seq-based stratification using our script 
outperformed stratification based on immunohistochemistry (IHC) analysis. The R 
package together with training data is available at GitHub: 
https://github.com/weiduweillcornell/ABC-GCB-classification-R-script.  
 
 
1.5 Deregulation of B cell receptor signaling and pathogenesis of activated B cell-like 
subtype of diffuse large B cell lymphoma 
  
The deregulation of B cell receptor (BCR) signaling is central to the pathogenesis of 
many B cell malignancies. It is especially central in the activated B cell-like subtype of 
diffuse large B cell lymphoma (ABC DLBCL). ABC DLBCLs exhibit chronic active 
BCR signaling, and are addicted to constitutive activation of downstream survival and 
proliferation signals such as NFkB(5). It has recently been found that a subset of the 
germinal center B cell like(GCB) subtype of DLBCLs are also dependent on BCR 
signaling through activation of the PI3K/AKT pathway(6). Multiple small molecule 
inhibitors against BCR signaling were developed and proved effective in killing BCR-
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dependent DLBCLs in vitro and in vivo(7-9). However when tested in clinical trials, 
single agent treatments again demonstrated limited responsiveness and efficacy(10), 
suggesting an urgent need for the design of effective combination therapies.  
 
1.6 Construction of computational model of the BCR signaling network and prediction 
of effective combination therapy 
 
In the second chapter, we present a kinetic modeling-based computational framework 
for predicting and optimizing combinatorial therapy against chronic active BCR 
signaling (Figure 1.1). We constructed a detailed kinetic model of the BCR signaling 
network parameterized by published signaling responses and protein concentrations.  
Mathematical models of proximal BCR signaling and downstream transcriptional 
network have been reported(11-13).  But to our knowledge, this is the first kinetic model 
to reconstruct the entire core BCR signaling network in silico. Using published drug 
response data in a BCR signaling-dependent cell line, we trained a tumor growth model 
which in combination with the kinetic model allowed us to simulate viability response 
upon various targeted treatments. Under this framework, we exhaustively tested the 
efficacy and synergism of all possible combinations of inhibition of eleven currently 
targetable kinases in the BCR signaling network. We discuss how these results pave the 
way for the discovery of effective drug combinations.  
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Figure 1.1 Outline of the approach taken in the present study. The central BCR 
signaling network was constructed based on validated protein-protein interactions from 
experimental literature. Parameters of molecular reaction kinetics were estimated from 
phosphorylation time course data and protein concentrations were retrieved from 
MOPED protein expression database. A phenotypic tumor growth model was trained 
on cell viability assays of inhibitor treatments to link signaling response to viability 
outcome. In the end, simulation of the signaling model in combination with the tumor 
growth model was conducted to optimize treatment strategy.  The model’s prediction 
was compared to published drug response data and new prediction-driven hypotheses 
were tested independently in vitro. 
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In this work, I developed the computational model and performed all the 
computational analysis including processing of the RNA-Seq data, model 
training and testing in microarray dataset and application of the model to RNA-
Seq data.   
 
This work serves as the main content of the third chapter.   
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CHAPTER TWO 
EFFECTIVE COMBINATION THEAPIES FOR B CELL LYMPHOMA 
PREDICTED BY A VIRTUAL DISEASE MODEL 
 
 
2.1 Kinetic modeling of BCR signaling network reproduces normal BCR signaling in 
silico 
 
We first curated the central BCR signaling network by gathering experimentally 
validated protein-protein interactions from literature. The reconstructed network is 
shown in Figure 2.1, and includes three major signaling pathways downstream of BCR, 
namely NFkB, PI3K/AKT and RAF/RAS/ERK. We chose to include these three 
pathways because they have been reported to closely regulate cell survival and 
proliferation in B cells and B cell malignancies(14).  
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Figure 2.1.  The central BCR signaling network constructed from literature. Antigen 
binding induces BCR aggregation and subsequent phosphorylation, which further 
triggers a complex signaling cascade initiated by phosphorylated LYN and SYK. The 
BTK-PLCg2-PKCb pathway activates downstream NFkB and ERK through divergent 
paths, while membrane recruitment of PI3K leads to AKT activation. Pathway 
crosstalks and feedback regulations are highly abundant in the network.   
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Antigen-induced BCR crosslinking allows SRC family kinases, mainly LYN, to 
phosphorylate the immuno-receptor tyrosine based activation motifs (ITAMs) of the 
intracellular BCR subunits Iga (CD79A) and Igb (CD79B)(15). Dually phosphorylated 
ITAM motifs then recruit SYK and activate it via tyrosine phosphorylation(16).  
Activated SYK phosphorylates adapter BLNK, which recruits BTK to the plasma 
membrane to facilitate its phosphorylation and subsequent activation by SYK and 
LYN(17). Activated BTK further phosphorylates PLCg2, which catalyzes the 
hydrolysis of phosphatidylinositol-4,5-bisphosphate (PI(4,5)P
2
) into diacylglycerol 
(DAG) and inositol trisphosphate (IP
3
)(18).  DAG together with elevated intracellular 
calcium induced by IP3 triggered endoplasmic reticulum (ER) calcium release activates 
PKCb(19), which then stimulates two divergent pathways that activate NFkB and ERK 
respectively.  Phosphorylation of CARD11 by PKCb leads to the assembly of the CBM 
complex composed of CARD11, BCL10 and MALT1(20). CBM acts as a scaffolding 
complex that facilitates IKK phosphorylation by TAK1, which in turn phosphorylates 
IKB and induces its degradation, releasing NFkB into the nucleus to elicit 
transcriptional activity(21). Additionally, protease activity of MALT1 positively 
regulates NFkB signaling by cleaving and inactivating inhibitors against NFkB 
activation such as A20 and RELB(22, 23). In the meantime, PKCb and DAG activate 
RASGRP, which triggers the canonical MAPK signaling cascade, leading to eventual 
phosphorylation and activation of ERK(24). On the other hand, SYK and LYN 
phosphorylate BCAP and CD19 respectively, which activate PI3K by membrane 
14	
	
recruitment(25, 26). PI(3,4,5)P
3 synthesized by PI3K further facilitates PDK1 catalyzed 
AKT phosphorylation by binding to both proteins via their plextrin homology (PH) 
domains(27).  Importantly, LYN negatively regulates PI3K signaling by activating 
SHIP1, which hydrolyzes PI(3,4,5)P
3
  into PI(4,5)P
2
 (28). 
Besides major signal transduction pathways as described above, our model includes key 
regulatory interactions in the BCR signaling network such as pathway crosstalks and 
feedback loops. The PI3K pathway positively regulates NFkB and ERK signaling by 
enhancing BTK membrane recruitment via PI(3,4,5)P
3
 binding. At the same time, it 
conversely attenuates ERK signaling via AKT catalyzed RAF phosphorylation(29).  It 
has recently been found that MEK negatively regulates PI3K/AKT signaling by 
recruiting PTEN to the plasma membrane(30), which dephosphorylates PI(3,4,5)P
3
 into 
PI(4,5)P
2
. BTK amplifies BCR signaling by two coupled positive feedback loops. It 
recruits PIP5K to the plasma membrane, which produces PI(4,5)P
2
 to sustain both 
PI(3,4,5)P
3
 synthesis and PI(4,5)P
2
 hydrolysis(31). Additionally, BTK phosphorylates 
BCAP, further facilitating the membrane recruitment of PI3K(25). The activity of BTK 
is attenuated by active PKCb via disruption of its membrane localization, constituting a 
negative feedback loop(32). Besides, another indirect feedback from PKC to SYK was 
added into the model as knockdown of PKCd was shown to mediate 
hyperphosphorylation of SYK(33). Furthermore, multiple negative feedback loops exist 
within the MAPK signaling cascade to fine-tune its activation amplitude and 
duration(34). 
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Instead of directly applying mass action kinetics to characterize elementary reactions in 
the network, we chose to adopt more streamlined mathematical representations derived 
from mass action law under reasonable assumptions. This strategy greatly reduced the 
number of variables, equations and most importantly parameters required in the 
mathematical model. As elementary protein-protein binding reactions generally reach 
equilibrium within seconds, we modeled them by deriving the steady-state relationships 
from mass action law.  
For a reversible protein-protein binding reaction,  
                                                                      k+ 																																																																			A + B ⇌ AB																																																									   (1) 
                                                                      k- 
at steady-state, 																																																															 AB = '(') A B 																																																								(2) 																																																														 A] + [AB = T- 																																																							(3) 																																																														 B] + [AB = T. 																																																					  (4) 
 
where [A] and [B] stand for the concentration of freed form of A and B; [TA] and [TB] 
stand for the total concentration of A and B; [AB] represents the concentration of the 
complex. By solving the above three equations, we have  
																															 AB = /01 23 0 24 5 (/01( 23 0 24 ))85918 23 24:1                          (5) 
 
where 𝐾 = <(<) , is the inverse of the dissociation constant Kd . 
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Under a few circumstances where a protein may bind to more than one partner, the 
interactions were considered independently for simplification.  
For enzymatic reactions such as phosphorylation or dephosphorylation, we adopted a 
classic Michaelis-Menten kinetic framework,   
 
                                                     							=>=? = <@AB C [D]EF0[D] 																																																												(6) 
 
where =>=?  is the rate of catalytic product formation, kcat is the turnover rate, Km is the 
Michaelis-Menten constant, [E] and [S] are concentration of enzyme and substrate 
respectively.  
 
Reactions in the BCR signaling network were written into corresponding equations 
according to rules discussed above. The full model consists of 28 state variables each 
representing concentration of a specific form of a protein species, depicted by 10 steady-
state equations and 18 ODEs(Figure 2.2).  
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Supplementary Text S1: Kinetic Model Equations
d[pBLNK]
dt
=
ksyk[pSY K]([TBLNK ]− [pBLNK])
Ksyk + [TBLNK ]− [pBLNK]
− kdblnk[TSHP1][pBLNK]
Kdblnk + [pBLNK]
d[pBCAP ]
dt
=
ksyk[pSY K]([TBCAP ]− [pBCAP ])
Ksyk + [TBCAP ]− [pBCAP ]
+
kbtk[pBTK]([TBCAP ]− [pBCAP ])
Kbtk + [TBCAP ]− [pBCAP ]
− kdbcapTd[pBCAP ]
Kdbcap + [pBCAP ]
d[pCD19]
dt
=
klyn[pLY N ]([TCD19]− [pCD19])
Klyn + [TCD19]− [pCD19]
− kdcd19Td[pCD19]
Kdcd19 + [pCD19]
d[pSHIP1]
dt
=
klyn[pLY N ]([TSHIP1]− [pSHIP1])
Klyn + [TSHIP1]− [pSHIP1]
− kdship[TPTP1B ][pSHIP1]
Kdship + [pSHIP1]
[BTK] =
(1 + kb1([pBLNK] + [TBTK ])−
√
(1 + kb1([pBLNK] + [TBTK ]))2 − 4k2b1[pBLNK][TBTK ]
2kb1(1 +Kpkbt[PKCβ])
+
(1 + kb2([PIP3] + [TBTK ])−
√
(1 + kb2([PIP3] + [TBTK ]))2 − 4k2b2[PIP3][TBTK ]
2kb2(1 +Kpkbt[PKCβ])
d[pBTK]
dt
=
ksyk[pSY K]([BTK]− [pBTK])
Ksyk + [BTK]− [pBTK]
+
klyn[pLY N ])([BTK]− [pBTK])
Klyn + [BTK]− [pBTK]
− kdbtkTd[pBTK]
Kdbtk + [pBTK]
[PI3K] =
(1 + kb3([pBCAP ] + [TPI3K ])−
√
(1 + kb3([pBCAP ] + [TPI3K ]))2 − 4k2b3[pBCAP ][TPI3K ]
2kb3
+
(1 + kb4([pCD19] + [TPI3K ])−
√
(1 + kb4([pCD19] + [TPI3K ]))2 − 4k2b4[pCD19][TPI3K ]
2kb4
d[pPLCγ2]
dt
=
kbtk[pBTK]([TPLC ]− [pPLCγ2])
Kbtk + [TPLC ]− [pPLCγ2]
− kdplc[TPTP1B ][pPLCγ2]
Kdplc + [pPLCγ2]
[PIP5K] =
(1 + kb5([BTK] + [TPIP5K ])−
√
(1 + kb5([BTK] + [TPIP5K ]))2 − 4k2b5[BTK][TPIP5K ]
2kb5
[PTEN ] =
(1 + kmept([pMEK] + [TPTEN ])−
√
(1 + kmept([pMEK] + [TPTEN ]))2 − 4k2mept[pMEK][TPTEN ]
2kmept
d[PIP2]
dt
= kPIP2 +
kpipi[PIP5K][Tpip]
Kpipi + TPIP
+
kptpiTPTEN [PIP3]
Kptpi + [PIP3]
− kpi3k[PI3K][PIP2]
Kpi3k + [PIP2]
− kplpi[pPLCγ2][PIP2]
Kplpi + [PIP2]
− γPIP2 [PIP2]
d[PIP3]
dt
=
kpi3k[PI3K][PIP2]
Kpi3k + [PIP2]
− kptpiTPTEN [PIP3]
Kptpi + [PIP3]
− kshpi[pSHIP1][PIP3]
Kshpi + [PIP3]
d[DAG]
dt
=
kplpi[pPLCγ2][PIP2]
Kplpi + [PIP2]
− γdag [DAG]
[PKCβ] =
(1 + kdapk([DAG] + [TPKCβ ])−
√
(1 + kdapk([DAG] + [TPKCβ ]))2 − 4k2dapk[DAG][TPKCβ ]
2kdapk
d[pCARD11]
dt
=
kpkc[PKCβ]([TCARD11]− [pCARD11])
Kpkc + [TCARD11]− [pCARD11]
− kdcardTd[pCARD11]
Kdcard + [pCARD11]
[CBM ] =
(1 + kb6([pCARD11] + [TMALT1])−
√
(1 + kb6([pCARD11] + [TMALT1]))2 − 4k2b6[pCARD11][TMALT1]
2kb6
d[pIKK]
dt
=
kcbik[CBM ]([TIKK ]− [pIKK])
Kcbik + [TIKK ]− [pIKK]
− kdikk ∗ Td ∗ [pIKK]
Kdikk + [pIKK]
d[NFκB]
dt
=
knfkb[pIKK]([TNFκB ]− [NFκB])
Knfkb + [TNFκB ]− [NFκB]
− γnfkb[NFκB]
[PDK1] =
(1 + kpdk1([PIP3] + [TPDK1])−
√
(1 + kpdk1([PIP3] + [TPDK1]))2 − 4k2pdk1[PIP3][TPDK1]
2kpdk1
[AKT ] =
(1 + kakt([PIP3] + [TAKT ])−
√
(1 + kakt([PIP3] + [TAKT ]))2 − 4k2akt[PIP3][TAKT ]
2kakt
d[pAKT ]
dt
=
kpdak[PDK1]([AKT ]− [pAKT ])
Kpdak + [AKT ]− [pAKT ]
− kdaktTd[pAKT ]
Kdakt + [pAKT ]
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Figure 2.2 Equations in kinetic model of BCR signaling network 
 
We modeled LYN and SYK as two independent input signals that triggered a 
downstream response. Their activation kinetics in normal B cells were approximated by 
double exponential functions where parameters in the functions were estimated by 
fitting to published phosphorylation time course data(35)(see below).  																																		𝑝𝐿𝑌𝑁 = 𝑓LMN ∗ 	𝑇LMN ∗ (𝐴 ∗ 𝑒5?/TU + 𝐵 ∗ 𝑒5?/T8)                      (7) 																																	𝑝𝑆𝑌𝐾 = 𝑇DME ∗ 	𝑇DME ∗ (𝐶 ∗ 𝑒5?/TY + 𝐷 ∗ 𝑒5?/T[)																												(8) 
 
where 𝑇LMN and 𝑇DME are total concentration of LYN and SYK respectively.  𝑓LMN and 𝑓DME are the phosphorylated fraction of LYN and SYK respectively. 𝑓LMN and 𝑓DME were 
estimated by fitting to the phosphorylation time course data using a genetic algorithm. 
A,B,C,D 𝜏/, 𝜏:, 𝜏_, 𝜏9.were estimated by fitting to the normalized pLYN and pSYK time 
course(35). 
[RASGRP ] =
(1 + kdara([DAG] + [TRASGRP ])−
√
(1 + kdara([DAG] + [TRASGRP ]))2 − 4k2dara[DAG][TRASGRP ]
2kdara
d[pRASGRP ]
dt
=
kpkc[PKCβ]([RASGRP ]− [pRASGRP ])
Kpkc + [RASGRP ]− [pRASGRP ]
− kdrasgrpTd[pRASGRP ]
Kdrasgrp + [pRASGRP ]
d[RAS]
dt
=
krara[pRASGRP ](TRAS − [RAS])
Krara + TRAS − [RAS] − kras[RAS]
[RAF ] =
(1 + kraf ([RAS] + [TRAF ])−
√
(1 + kraf ([RAS] + [TRAF ]))2 − 4k2raf [RAS][TRAF ]
2kraf (1 +Kerra[pERK] +Kakra[pAKT ])
d[pMEK]
dt
=
krame[RAF ](TMEK − [pMEK])
Krame + TMEK − [pMEK] −
kdmekTd[pMEK]
Kdmek + [pMEK]
d[pMEK∗]
dt
=
kerme[pERK]([pMEK]− [pMEK∗])
Kerme + [pMEK]− [pMEK∗] −
kdmek∗Td[pMEK∗]
Kdmek∗ + [pMEK∗]
d[pERK]
dt
=
kmeer([pMEK]− [pMEK∗])(TERK − [pERK])
Kmeer + TERK − [pERK] −
kderkTd[pERK]
Kderk + [pERK]
Supplementary Table S1: List of kinetic parameters in the
model
Parameter Description Reference
klyn = 1380/min,Klyn = 82 µM LYN phosphorylation [9]
ksyk = 180/min,Ksyk = 6.9 µM SYK phosphorylation [37]
kbtk = 8.4/min,Kbtk = 37 µM BTK phosphorylation [8]
kpkc = 46/min,Kpkc = 57 µM PKCβ phosphorylation [26]
kb1 = 0.5/µM, kb2 = 1.25/µM BTK recruitment by BLNK or PIP3 [38][32]
Kpkbt BTK binding hibition by PKCβ
kb3, kb4 PI3K recruitment by BCAP or CD19
kb5 PIP5K recruitement by BTK
kpipi = 1.8/min,Kpipi = 1.2 µM PIP2 synthesis by PIP5K [3][44]
kptpi = 73/min,Kptpi = 5 µM PIP3 dephosphorylation by PTEN [27]
kpi3k = 186/min,Kpi3k = 3.5 µM PIP2 phosphorylation by PI3K [6]
kplpi = 602/min,Kplpi 440 µM PIP2 hydrolysis by PLCγ2 [2]
kpip2 , γpip2 PIP2 synthesis and degradation
kshpi = 522/min,Kshpi = 46 µM PIP3 dephosphorylation by SHIP1 [43]
γdag DAG degradation
kdapk = 200/µM PKCβ activation by DAG [1]
kpkca = 46/min,Kpkca = 57 µM CARD11 phosphorylation by PKCβ [26]
kb6 CBM complex recruitment by pCARD11
kcbik, Kcbik IKK phosphorylation by CBM
knfkb = 1.7/min,Knfkb = 2.6 µM NFκB freed from IκB phosphorylation [19]
γnfkb = 6/min NFκB transportation into nucleus [40]
kpdk1 = 5000/µM PDK1 recruitment by PIP3 [45]
kakt = 1.7/µM AKT recruitment by PIP3 [15]
kpdak = 21/min,Kpdak = 80 µM AKT phosphorylation by PDK1 [16]
kdara = 667/µM RASGRP activation by DAG [25]
krara = 234/min,Krara = 386 µM RASGRP activated RAS/GDP dissociation [24]
kras RAS deactivation
kraf = 12/µM RAF activation by RAS [17]
Kerra, Kakra RAF inhibition by ERK and AKT
krame = 11/min,Krame = 0.8 µM MEK ph sphorylation by RAF [14]
kerme = 130/min,Kerme = 4.6 µM MEK phosphorylation by ERK [31][11]
kmeer = 1.5/min,Kmeer = 0.3 µM ERK phosphorylation by MEK [12][21]
kmept PTEN recruitment by MEK
kdbcap, Kdbcap BCAP dephosphorylation
kdblnk, Kdblnk BLNK dephosphorylation
kdcd19, Kdcd19 CD19 dephosphorylation
kdship, Kdship SHIP dephosphorylation
kdplc, Kdplc PLCγ2 dephosphorylation
kdbtk, Kdbtk BTK dephosphorylation
kdcard, Kdcard CARD11 dephosphorylation
kdakt, Kdakt AKT dephosphorylation
kdrasgrp, Kdrasgrp RASGRP dephosphorylation
kdmek, Kdmek MEK dephosphorylation
kdmek∗ , Kdmek∗ MEK∗ dephosphorylation
kderk, Kerk ERK dephosphorylation
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To parameterize the model, we first retrieved protein concentrations in B lymphocytes 
quantified by mass-spectrometry from the MOPED protein expression database(36) and 
literature(37, 38) (Table 2.1). 
 
Table 2.1 Table of total protein concentration in the kinetic model 
 
 
 
We then used genetic algorithms to optimize the remaining 72 kinetic parameters within 
bounded biologically reasonable ranges(39-41) (Table 2.2) by minimizing residual sum 
Parameter Description Reference
[TLY N ] = 1.18µM total concentration of LYN (36)
[TSYK ] = 3.27µM total concentration of SYK (36)
[TBLNK ] = 0.65µM total concentration of BLNK (36)
[TBCAP ] = 0.9µM total concentration of BCAP (36)
[TCD19] = 0.83µM total concentration of CD19 (36)
[TSHIP1] = 2.82µM total concentration of SHIP1 (36)
[TBTK ] = 1.49µM total concentration of BTK (36)
[TPI3K ] = 0.33µM total concentration of PI3K (36)
[TPTEN ] = 0.02µM total concentration of PTEN (36)
[TPLC 2] = 2.57µM total concentration of PLC 2 (36)
[TPIP5K ] = 4.4µM total concentration of PIP5K (36)
[TPKC  ] = 2.5µM total concentration of PKC  (36)
[TCARD11] = 0.3µM total concentration of CARD11 (36)
[TIKK ] = 0.71µM total concentration of IKK (36)
[TPDK1] = 0.27µM total concentration of PDK1 (36)
[TAKT ] = 0.2µM total concentration of AKT (36)
[TNFB ] = 0.81µM total concentration of NFB (36)
[TSHP1] = 6.9µM total concentration of SHP1 (36)
[TPTPT1B ] = 1.48µM total concentration of PTP1B (36)
[TRASGRP ] = 1.03µM total concentration of RASGRP (36)
[TRAS ] = 0.15µM total concentration of RAS (36)
[TRAF ] = 1.1µM total concentration of RAF (36)
[TMEK ] = 1.39µM total concentration of MEK (36)
[TERK ] = 2.26µM total concentration of ERK (36)
[TMALT1] = 0.23µM total concentration of MALT1 (36)
[Td] = 1.0µM total concentration of unidentified phosphatase Estimate
[TPIP ] = 5µM total concentration of PIP (37)(38)
1
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of squares between simulated phosphorylation time courses and published western blot 
data(35).  
 
Table 2.2  Kinetic parameter bounds 
 
 
Experimental data and simulated results were each normalized to their respective 
maximum value for comparison. 10 sets of kinetic parameters were identified from 5000 
independent runs that fit almost equally well(42).  Simulated trajectory under these 10 
parameter sets together with phosphorylation time course data are shown in Fig 2.3.  
 
 
Parameter Kd kcat Km
Range 0.1nM   1mM 0.1  104 s 1 0.1nM   1mM
Reference (39) (40)(41) (39)
1
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Figure 2.3 Simulated normal BCR signaling. Trajectory of ten parameter sets were 
shown in comparison with published phosphorylation time course data. 
 
To examine if our fitting method is prone to overfitting problem, we manually injected 
different levels of white noise into the training time course data and refitted the model 
using our genetic algorithm. The simulation was done using optimized parameter values 
as initial population of parameter choice and 10 independent optimization processes 
were performed for each noise level. We showed that the residual sum of square greatly 
increases as the noise level increases (Figure 2.4). This indicates that the model is not 
prone to fitting to noise.  
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Figure 2.4 Residual sum of square as a function of signal-to-noise ratio 
 
We performed parameter sensitivity analysis where each parameter was perturbed 
independently across four orders of magnitudes and viability response was recorded. 
We found overall robustness and identified the most sensitive parameters as parameters 
regulating main axis of the NFkB pathway(Figure 2.5).  
 
 
 
 
 
 
 
 
Supplementary Figure S2: Residual as a function of noise
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Figure S2. Residual sum of square as a function of signal-to-noise ratio.
Supplementary Figure S3: Simplified Boolean network model
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Figure S3. Simplified BCR signaling network consisting of only the 11 targetable nodes together
with signaling pathway end points and a node representing cell viability.
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Figure 2.5 Parameter sensitivity analysis. Bars show standard deviation of viability 
response across 4 orders of magnitude perturbation.  
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Supplementary Figure S1:Parameter sensitivity analysis
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Figure S1. Parameter sensitivity analysis - standard deviation of viability response across 4 orders
of magnitures perturbation.
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We note that predicted activation time course of BLNK, PLC and PKC deviate from 
experimental data. We believe that the most likely reason behind this relatively poor fit 
may be currently unknown regulatory interactions involving additional proteins in the 
BCR signaling pathway. However the relatively poor fit in these components in the 
upstream of NFkB pathway would not significantly influence the model’s predictions 
as our parameter sensitivity analysis indicates viability response is most sensitive to 
parameters in the downstream part of the NFkB pathway (Figure 2.5). Of note, we were 
independently able to find 39 kinetic parameter values from the literature(42), and we 
compared these values with the range of estimated 10 parameter sets (Figure 2.6). By 
shuffling the literature-retrieved parameters 10,000 times, we found that the literature-
retrieved parameter values fall within the estimated parameter ranges significantly more 
often than random (p=0.05)(Figure 2.7). We note however that many discrepancies 
were found between estimated and published parameters (Figure 2.6). We speculate 
that many of these discrepancies are likely due to in vitro nature of the experiments used 
to quantify kinetic parameters.  
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Figure 2.6 Comparison between literature-retrieved parameter values with simulation-
estimated parameter ranges. Box-plot indicates the simulation-estimated parameter 
ranges while red dots represent literature-retrieved parameter values. 
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Figure 2.7 Empirical cumulative distribution of the number of parameters that would 
fall within simulation-estimated parameter ranges by chance derived by shuffling the 
literature-retrieved parameters 10,000 times. 
 
1.2 Combining BCR signaling model with a tumor growth model predicted cell viability 
response upon single and combinatorial drug treatments in a BCR signaling-dependent 
ABC DLBCL cell line  
 
We next sought to simulate the effect of various small molecule inhibitors on ABC 
DLBCL cell viability and to compare simulation results with published drug response 
data in a BCR signaling dependent ABC-DLBCL cell line TMD8(43). We selected 
TMD8 because of the extensive drug combinatorial data available on this cell line(43). 
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We first made several modifications to the model to accommodate the differences 
between normal BCR signaling and aberrant BCR signaling in ABC DLBCL. Instead 
of applying a temporal upstream stimulus, we assumed constitutive LYN and SYK 
phosphorylation as observed both in ABC DLBCL cell lines and in primary DLBCL 
patient samples(5, 44). Additionally, we accounted for genetic alterations in members 
of the BCR signaling network in TMD8 compared to normal B cells. Specifically, 
TMD8 was shown to carry CD79B mutation that attenuates LYN activity by 
approximately 80%(5). Correspondingly we decreased the enzymatic activity of LYN 
in the model to the same extent. 
In contrast to the temporal activation dynamics of normal BCR signaling, we imposed 
constitutive pLYN and pSYK stimulus in simulations of diseased ABC DLBCLs, with 
negative feedback from SYK and PKC respectively.  
																																			𝑝𝐿𝑌𝑁 = 0.2 ∗ 𝑓LMN ∗ 𝑇LMN/(100 ∗ 𝑝𝑆𝑌𝐾)																																						(9) 																																			𝑝𝑆𝑌𝐾 = 𝑓DME ∗ 𝑇DME/(1 + 100 ∗ 𝑃𝐾𝐶)																																										(10) 𝑇ℎ𝑒	0.2 coefficient is to account for LYN attenuation effect due to CD79B mutation in 
TMD8. The parameter for negative feedback is estimated by fitting to single drug 
viability response(43). 
 
To predict cell viability response from signaling output, we formulated a tumor growth 
model in which the growth rate of tumor cells is dependent on the weighted sum of the 
three downstream survival and proliferation signals NFkB, ERK and AKT through a 
Hill function. A similar formalism has been used to characterize tumor growth of 
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ERBB-amplified breast cancer driven by ERK and AKT activation(45). 
Assume a tumor cell population is at exponential growth phase(46, 47), 																																																																		𝑁 = 𝑁e𝑒(f5fg)?																																																								 (11) 
where N0 and N are cell number at time 0 and time t, 𝑟= is basal death rate, while growth 
rate 𝑟 is dependent on three downstream survival and proliferation signals NFkB, pAKT, 
and pERK (normalized by untreated control) through a Hill function,  																																									𝑟 = 𝑟∗ ∗ (iU∗Njkl0i8∗mnEo0iY∗mCpE)qEq0(iU∗Njkl0i8∗mnEo0iY∗mCpE)q																																		 (12) 
Here r* is basal growth rate, n is Hill coefficient, w1,w2,w3 are the estimated weights of 
three signaling outputs NFkB, pAKT and pERK. Therefore, viability response defined 
as the ratio of cell number monitored under treated condition 𝑁 (for a time span of 𝑇) 
and untreated control 𝑁r can be predicted as following,  
																	𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = NN@ = 𝑒f∗∗o( zU∗{|}~(z8∗(zY∗ qq( zU∗{|}~(z8∗(zY∗ q5 (zU(z8(zY)qq((zU(z8(zY)q)						 (13) 
Parameters required in this function were trained with viability data of three single drug 
viability responses, namely NFkB, AKT and MEK inhibitor respectively. First the level 
of the three downstream survival and proliferation signals were predicted via simulation 
of the signaling model, and then input into the tumor growth functions to compute the 
viability output. Parameters were chosen by minimizing the sum of residuals between 
the viability predictions and experimental data. 
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We used published viability response data in TMD8 to parameterize the tumor growth 
model, where cells were treated with IKK, AKT and MEK inhibitors at multiple 
dosages(43). Specifically, using the median effect equation, we calibrated the percent 
activity left on the targeted kinase for each inhibitor at a given dosage based on the 
inhibitor’s IC50 value (Table 2.3).  
                                            							%𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = //0(gA )F																																															(14) 
The drug’s IC50 was taken from literature(8, 48-58) (Table 2.3), while m was assumed 
to be 1 under a first order approximation. Then the activity of the targeted kinase (i.e. 
parameters representing catalytic or activation rate of targeted kinase) was reduced to 
the corresponding percentage in the kinetic model. We list perturbed parameters in each 
simulated inhibitor treatment in Table 2.3.  
Table 2.3 Inhibitors against BCR signaling network 
 
 
Target Inhibitor IC50 Perturbed parameter Reference
LYN Saracatinib(AZD0530) 5 nM fLY N (48)
SYK PRT060318 4 nM fSYK (49)
BTK Ibrutinib(PCI-32765) 0.5 nM kbtk (50)
PKC  Sotrastaurin(AEB071) 2 nM kpkc, Kpkbt (51)
MALT1 MI-2 5.84 µM kcbik (8)
IKK NCGC00161703 67 nM knfkb (52)
PI3K  CAL-101 2.5 nM kpi3k (53)
BKM-120 116 nM kpi3k (54)
PDK1 BX-795 6 nM kdpak (55)
AKT MK-2206 8 nM pAKT, Kakra (56)
RAF CHIR-265 30 nM krame (57)
MEK Trametinib 0.92 nM kmeer (58)
1
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We then reduced the activity of the targeted kinase to the same level in the model and 
simulated steady-state signaling output. Parameters in the tumor growth model were 
estimated by minimizing residual sum of squares between predicted viability response 
and experimental data.  
We first simulated single drug viability response of inhibitors covering the NFkB, 
PI3K/AKT and MAPK pathway and compared to experimental data. We observed that 
in silico simulation with the BCR signaling model and the tumor growth model 
recapitulated the viability response of the three training single drug response, namely 
IKK, AKT, MEK inhibitors (Figure 2.8A). This is not surprising since the growth 
model was fitted based on training data. As independent predictions, we also simulated 
drug response of inhibitors targeting other kinases in the network, e.g. CAL-101 against 
PI3K, Ibrutinib against BTK, and found that predicted viability response matched 
favorably with TMD8 drug response data (Figure 2.8B). At the same time, we found 
simulated viability response of SYK inhibition to deviate from experimental data (grey 
line), yet this discrepancy can be partially rescued by adding a negative feedback from 
SYK to LYN (blue line). It has been reported that SYK functions as a negative regulator 
of BCR signaling by phosphorylating Ig-a. Since Ig-a primarily interacts with LYN, 
we assumed in the model that SYK indirectly negatively regulates LYN.  
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Figure 2.8 Training and prediction of single drug viability response in ABC DLBCL 
cell line TMD8. (A) Tumor growth model parameterization using single drug viability 
response of inhibitors targeting NFkB, AKT and MEK. Gray dashed lines correspond 
to simulation results of model without SYK to LYN negative feedback, while brown 
dashed lines correspond to simulation results of model without PI3K-NFkB crosstalk. 
(B) Single drug viability response of inhibitor targeting various kinases against BCR 
signaling network. 
Beyond single drug viability response, we also simulated combinatorial drug response 
of Ibrutinib in combination with various other kinases targeting the BCR pathway, and 
observed the predicted response contour to match favorably with experimental results 
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(Figure 2.9). These results demonstrate that our model can correctly capture the 
interaction between inhibitors as well.  
 
Figure 2.9 Combinatorial drug viability responses of BTK inhibitor Ibrutinib in 
combination with additional inhibitors targeting BCR network intermediates were 
predicted and compared with experimental data. 
Overall, these results suggest that viability response of small molecule inhibitors 
targeting the BCR signaling network can be predicted via in silico simulation of the 
BCR signaling model in combination with the tumor growth model.  
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2.3 Crosstalk between PI3K and NFkB pathway mediates efficacy of PI3K inhibition 
in TMD8 
In both the drug response data and model’s simulation, we observed that PI3K inhibition 
is significantly more effective at inhibiting tumor growth than blockage of its 
downstream effector AKT. A similar phenomenon was reported in other studies, where 
PI3K inhibition was shown to attenuate NFkB transcriptional activity(6, 59). We 
hypothesized that the efficacy of PI3K inhibition is primarily attributed to suppression 
of NFkB signaling, which is mediated by upstream crosstalk between the PI3K and 
NFkB pathways. To test this hypothesis, we abolished the crosstalk between PI3K and 
NFkB by knocking out in silico PI(3,4,5)P
3
 -mediated membrane recruitment of BTK 
in the signaling model.  Under this condition we re-simulated the viability response of 
PI3K inhibition, which showed significant reduction compared to both experimental 
data and simulation with the full signaling model (Figure 2.8, brown line). This result 
supports the notion that the upstream crosstalk between PI3K and NFkB pathway is 
critical in mediating tumor growth inhibition by PI3K inhibitor. It also provides further 
rational support for the clinical use of PI3K inhibitors in DLBCL that are dependent in 
NFkB signaling(6, 59).  
 
2.4 Computational optimization of targeted therapy against chronic active BCR 
signaling  
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Using the above modeling framework, we sought to identify targeted therapies against 
the BCR signaling network that most effectively inhibit tumor growth. We exhaustively 
tested all drug pairs based on 11 small molecule inhibitors currently available that target 
various kinases in the network, yielding 55 treatment strategies in total.  In each scenario 
viability response was simulated at 10 by 10 virtual dosages where each targeted kinase 
was inhibited at 0% to 99% evenly spaced in log10 space. We calculated area under the 
combinatorial viability response surface as an overall indicator of drug combination 
potency. The smaller the value is, the more potent the drug target combination is (Figure 
2.10A). We found that under the same inhibition potency, efficacy of different treatment 
strategies was highly variable, ranging from almost no growth inhibition to up to 80% 
reduction (Figure 2.10B). Specifically, inhibiting downstream of the NFkB signaling 
pathway, especially through MALT1 and IKK inhibitor, exhibited the most prominent 
efficacy, and combined MALT1 and IKK blockage yielded highest tumor growth 
inhibition. In comparison, tumor cell growth was relatively insensitive to blockage of 
MAPK pathway in our simulations.  In summary, this computational screening result 
suggests that various treatment strategies against a signaling network can yield highly 
variable therapeutic responses and that in silico simulation can help identify targets that 
confer intrinsic vulnerability.  
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Figure 2.10 Computational optimization of treatment strategy against chronic active 
BCR signaling (A) Viability response surface of three drug target combinations. Two 
horizontal axis corresponds to virtual dosage of two different inhibitors while the 
vertical axis indicates cell viability normalized to untreated condition. For each drug 
target combination, 10 virtual dosages (between 0% to 99% inhibition evenly spaced in 
log10 space) of each single drug are tested. (B) Barplot of simulated viability response 
of all possible dual inhibition on 11 kinases in the BCR signaling network that are 
currently targetable. Here viability responses are calculated area under the 
combinatorial viability response surface (as shown in Fig 6A) as an overall indicator of 
drug combination potency. Binary codes on the bottom indicate the treatments applied 
(black represents targeted inhibition).  
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We then sought to identify drug combinations that are synergistic via computational 
simulations. For a given two-drug combination, the combinatorial drug response at 10 
by 10 virtual dosage as discussed above were used to estimate mode of drug interaction 
under the Bliss independence model.  
Under the Bliss Independence model, the additive effect of two inhibitors is computed 
as the multiplication of the effect of individual inhibitors,  
																																																							𝐹n = 𝐹nU ∗ 𝐹n8																																																													(15) 
where 𝐹n indicates the fraction unaffected. To evaluate mode of interaction between 
two inhibitors, we computed viability response at 10x10 virtual dosages by varying the 
percent inhibition of each targeted kinase independently from 0% to 90% at 10% 
interval. These viability values were used to estimate parameter that minimizes the 
following metric,  
																																										 (𝐹nU8 − 𝛽 ∗ 𝐹nU ∗ 𝐹n8):																																																	 (16) 
where x,y are virtual dosages for inhibitor 1 and 2 respectively. 𝛽 < 1, 𝛽 = 1, 𝛽 > 1 
indicates synergism, additive and antagonism respectively.  
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Computational screening predicted dual blockage of LYN and SYK as the most 
synergistic combination(Figure 2.11A). To test this prediction, we treated ABC 
DLBCL cell lines TMD8, HBL1 and OCI-LY10 with LYN inhibitor Dasatinib and SYK 
inhibitor R406, at multiple doses. Comparing combinatorial drug response data to 
theoretical additive response predicted by the Bliss independence model, we confirmed 
synergism between Dasatinib and R406 (Figure 2.11B).  We also tested and confirmed 
the predicted antagonism between dual SYK and MALT1 inhibition using SYK 
inhibitor R406 and MALT1 inhibitor MI-2 across three ABC DLBCL cell lines (Figure 
2.11B). 
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Figure 2.11. Prediction and validation of synergistic and antagonistic drug 
combinations. (A) Modes of interaction of all pairwise inhibitions under Bliss 
Independence model.  b<1, b=1, b>1 correspond to synergism, additive and antagonism 
respectively. (B) In vitro validation of predicted synergistic and antagonistic drug 
combination in ABC DLBCL cell line TMD8, HBL1 and OCI-LY10. R406, Dasatinib 
and MI-2 are inhibitors against SYK, LYN and MALT1 respectively.    
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2.5 Comparison of the kinetic model to a simpler Boolean network model 
 
In this work, we choose to develop a highly detailed kinetic model of the BCR signaling 
network, modeling direct protein-protein interactions using highly quantitative ODEs 
wherever possible. We note that there are other simpler modeling techniques for 
analysis of signaling pathways, e.g. simplifying signaling cascades as coupled Hill 
functions(45) or using Boolean network models. To investigate the predictive power of 
a simpler model, we constructed a Boolean model of a simplified BCR signaling 
network consisting of only the 11 targetable nodes together with signaling pathway end 
points and a node representing cell viability (Figure 2.12).  
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Figure 2.12. Simplified BCR signaling network consisting of only the 11 targetable 
nodes together with signaling pathway end points and a node representing cell viability.  
 
In this model, each node has only two states (0-inactive and 1-active), and the state value 
in a particular step is determined by the values of all its regulators in the previous step. 
A node will be active if the majority of its regulators are activating, except that the 
Viability node is active when any of the signaling outputs is active. Assuming the two 
input nodes LYN and SYK are constitutively active, all possible initial states (2^12) are 
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Figure S2. Residual sum of square as a function of signal-to-noise ratio.
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Figure S3. Simplified BCR signaling network consisting of only the 11 targetable nodes together
with signaling pathway end points and a node representing cell viability.
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exhaustively simulated until reaching attractors. These initial states ended up in two 
attractors, both attractors consisting of states in which Viability is on (Figure 2.13).  
 
Figure 2.13  Attractor landscape of Boolean network model. 
 
 Then all two drug combinations were tested. To simulate drug-mediated inhibition, 
each targeted node was made constitutively inactive. There are four drug combinations 
that result in a single global attractor in which Viability is off. These four drug 
combinations are BTK-MEK, BTK-RAF, SYK-MEK, SYK-RAF.  These four drug 
combinations ranked low in the drug efficacy predictions made by the full ODE model 
(Figure 2.10B). Moreover, experimental data in TMD8 cell line(43) indicates that the 
Supplementary Figure S4: Attractor landscape of Boolean
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Figure S5. Viability response of drug combination BTK+MEK and BTK+RAF in TMD8. Ibru-
tinib, trametinib and chir-265 are inhibitors of BTK, MEK and RAF respectively.
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BTK-MEK and BTK-RAF combinations are not very effective in decreasing cell 
viability – the MEK and RAF inhibitors are not responsive (along the y axis) and 
synergism is lacking (Figure 2.14).   
 
 
Figure 2.14 Viability response of drug combination BTK+MEK and BTK+RAF in 
TMD8. Ibrutinib, Trametinib and CHIR-265 are inhibitors of BTK, MEK and RAF 
respectively.  
 
Overall, these results suggest that a simple Boolean network model is not able to capture 
the same results as the full ODE model and that its prediction accuracy is lacking when 
compared to experimental data. 
 
 
 
Supplementary Figure S4: Attractor landscape of Boolean
network model

	

	
Figure S4. Attractor landscape of Boolean network model.
Supplementary Figure S5: Viability response of drug combi-
nation BTK+MEK and BTK+RAF in TMD8
0.13
0.18
0.18
0.25
0.20
0.26
0.24
0.25
0.26
0.25
0.26
0.33
0.32
0.32
0.43
0.35
0.44
0.49
0.49
0.62
0.57
0.70
0.83
0.96
0.69
0.81
0.89
0.89
0.80
1.02
0.83
0.85
0.92
0.80
0.91
1.00
50 12.5
3.125
0.781
0.195
0
2500
625
156.25
39.06
9.77
0






0.11
0.16
0.15
0.25
0.24
0.25
0.20
0.21
0.26
0.33
0.30
0.29
0.29
0.35
0.36
0.47
0.41
0.42
0.78
0.59
0.66
0.84
1.03
0.85
0.92
0.88
0.98
0.93
1.22
0.99
0.88
0.98
0.99
0.91
1.04
1.00
50 12.5
3.125
0.781
0.195
0
2500
625
156.25
39.06
9.77
0
5 0
0.2
0.4
0.6
0.8
1
1.2


 "!



	
	 	
Figure S5. Viability response of drug combination BTK+MEK and BTK+RAF in TMD8. Ibru-
tinib, trametinib and chir-265 are inhibitors of BTK, MEK and RAF respectively.
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CHAPTER THREE 
PREDICTING ABC VS. GCB SUBTYPES OF DIFFUSE LARGE B CELL 
LYMPHOMA FROM RNA-SEQ DATA 
 
3.1  Z score normalization and Bayesian classifier for ABC/GCB DLBCL classification 
 
We use the microarray dataset from Lenz et al.(60) as training data, which has 
predetermined ABC/GCB classification labels. With the goal of being able to classify 
datasets from different platforms, we first apply z score standardization to both training 
and the to-be-classified data, where we center and scale each gene across all samples 
and then perform log transformation to make the data more normally distributed (Figure 
3.1). This procedure puts the two datasets into comparable scale and distribution.  Then 
we select the top N (default to 50) most differentially expressed genes ranked by p value 
between the ABC and GCB groups in the training data as determined by student’s t-test 
as genes in the Bayesian predictor. A linear predictor score(LPS) for each sample in the 
training and to-be-classified data is then calculated,  
 
𝐿𝑃𝑆(𝑋) = 	 𝑎𝑋e/  
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where 𝑋 is the expression level of j th gene in the predictor and 𝑎 is the t statistic of j 
th gene in the t test. Then we calculate the likelihood that a sample is in each of the two 
subgroups by applying Bayes’rule:  
 
𝑃 𝑋	𝑖𝑛	𝑔𝑟𝑜𝑢𝑝	1 = ϕ(LPS(X); 𝜇/, 𝜎/:)ϕ(LPS(X); 𝜇/, 𝜎/:) + ϕ(LPS(X); 𝜇:, 𝜎::) 
 
where ϕ(LPS(X); 𝜇, 𝜎:)  represents the normal density function given mean 𝜇  and 
variance 𝜎: estimated from a training set subgroup.  We set 90% certainty as cutoff for 
subgroup assignment.  
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Figure 3.1 Diagram of the approach taken in the study. First z score standardization 
following log transformation is performed in both training and to-be-classified data 
respectively. Then top 50 most differentially expressed genes between ABC and GCB 
groups are determined by student’s t-test in the training data set. These 50 genes are 
used to form a linear predictor. Samples are then classified into ABC vs. GCB groups 
according to Bayes’rule. 
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Log transform of Z-score standardization on training and to-be-classified data
respectively
Sample 1 … Sample N
Gene 1
…
Gene M
Training data To-be-classified data
Student’s t test to determine the top N most
differentially expressed genes in the predictor
Sample 1 … Sample N
Gene 1
…
Gene M
Calculate Linear Predictor Score(LPS) for each sample in the training and
to-be-classified data!"# $ = &'($()(*+
"($	./	012341) = 7(!"# $ ; 9̂+,<=+>)	7 !"# $ ; 9̂+,<=+> + 7(!"# $ ; 9̂>,<=>>)
Calculate	the	likelihood	that	a	sample	is	in	each	of	the	two	subgroups	by	
applying	Bayes’ rule	
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3.2 Testing the ABC/GCB classifier within the pre-labeled microarray dataset 
To test the performance of the ABC/GCB classifier, we randomly equally divided the 
pre-labeled microarray dataset into a training (37 ABCs, 36 GCBs) and a validation set 
(37 ABCs, 35 GCBs). We then performed student’s t-test on the training set to determine 
50 top differentially expressed genes between ABC/GCB as predictors. Then we 
calculated the LPS for each sample and applied Bayes’ rule to each sample to assign a 
label(ABC, GCB or unclassified). Then we compared model-derived classification to 
existing labels (Figure 3.2). The overall consistency was 100% in the training set and 
93.1% in the validation set. Similar consistency was achieved when the top 25 (97.3% 
in the training set and 93.1% in the validation set) or top 100 (97.3% in the training set 
and 90.3% in the validation set) differentially expressed genes were selected instead of 
top 50.  
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Figure 3.2 Classification on microarray dataset and comparison to pre-existing labels. 
ClassifiedLabel corresponds to Bayesian classifier predicted subtype while Subtype 
corresponds to pre-labeled subtype (A) Classification of training set. (B) Classification 
of validation set. 
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(Continued	Figure	3.2)	
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3.3   Applying ABC/GCB classifier to clinic cohort and comparison with IHC label and 
Lymph2Cx 20 gene signature profiling. 
 
We then sought to test the ABC/GCB classifier on an RNA-Seq dataset by applying it 
to a cohort consisting of 68 DLBCL patients. Upon alignment using STAR(61), FPKM 
values of RNA-Seq profiles were calculated using Cufflinks(62) with default 
parameters. Within the top 50 most differentially expressed genes in the labeled 
microarray dataset, 45 genes are present in the RNA-Seq dataset. We therefore used 
these 45 genes as genes in the predictor to classify ABC and GCB subtypes. To 
maximize predictive power, all microarray data with ABC/GCB label was used for 
training. Out of the 68 DLBCL patient samples, 30 were classified as ABC and 30 were 
classified as GCB, with a remaining 8 being unclassified. 
 
We first compared the RNA-Seq based ABC/GCB classification to 
immunohistochemistry (IHC) labels. The overall consistency is 46.4%(Figure 3.3). By 
randomly permuting both the RNA-Seq based classification labels and IHC labels 
10,000 times, we determined that this consistency is not statistically significant 
(p=0.234).  
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Figure 3.3  Classification of RNA-Seq data and comparison to IHC labels. 
ClassifiedLabel corresponds to Bayesian classifier predicted subtype while Subtype 
corresponds to IHC determined subtype. 
 
 
We then compared our classification to Lymph2Cx 20 gene signature profiling(63). 
This 20 gene signature consists of 8 genes being overexpressed in ABC DLBCLs, 5 
house-keeping genes, and 7 genes being overexpressed in GCB DLBCLs. We applied 
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hierarchical clustering to the centered and scaled 20 gene expression signature RNA-
Seq data (Figure 3.4A). The result demonstrates good consistency with our 
classification, where ABC or GCB samples are largely clustered independently. This is 
not surprising as we note that most of the genes included in the Lymph2Cx 20 gene 
signature (excluding the 5 house-keeping genes) are present in our classifier(Figure 
3.4B). 
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Figure 3.4 Hierarchical clustering based on Lymph2Cx 20 gene signature profiling and 
comparison between genes in Bayesian classifier and in Lymph2Cx 20 gene signature. 
(A) Hierarchical clustering based on Lymph2Cx 20 gene signature profiling. (B) Venn 
diagram showing overlap between genes in RNA-Seq Bayesian classifier and 
Lymph2Cx 20 gene signature. Blue corresponds to RNA-Seq Bayesian classifier while 
pink corresponds to Lymph2Cx 20 gene signature. 
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(Continued	Figure	3.4)	
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3.4 RNA-Seq based ABC/GCB classifier outperformed IHC label in stratifying two 
subgroups with distinct probability of survival.  
 
Since the consistency between RNA-Seq based ABC/GCB classification and IHC-based 
labeling is low, we sought to compare how each classification associates with survival 
probability.  Using Kaplan-Meier plots, we found that the IHC-based labeling is not able 
to stratify two groups with distinct survival probability while the RNA-Seq based 
classification succeeded (Figure 3.5). P values were determined using a one variable 
Cox model and confirmed the results shown in the Kaplan-Meier plots. We also 
investigated the performance of a Bayesian classifier built on genes in the Lymph2Cx 
profiling. For this classifier, 14 genes that discriminate between ABC and GCB subtype 
(excluding the 5 house keeping genes) and are present in both the microarray training 
data and RNA-Seq data are used to construct the predictor. We found that classification 
based on these 14 genes gave less significant survival stratification probability 
compared to our classifier (Figure 3.5).  
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Figure 3.5  Kaplan-Meier plots of patient survival in subgroups defined by IHC labels 
or RNA-Seq classification. P values were determined by one variable Cox model. (A) 
Two groups represent IHC labeled ABC or GCB subtype. (B) Two groups represent 
ABC or GCB classification based on our RNA-Seq Bayesian classifier (C) Two groups 
represent ABC or GCB classification based on RNA-Seq Bayesian classifier with 
Lymph2Cx genes. 
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CHAPTER FOUR DISCUSSION 
 
It is increasingly acknowledged that aberrant BCR signaling plays a central role in the 
development and maintenance of many B cell malignancies(64). Though a large panel 
of small molecule inhibitors against BCR signaling have been developed, rational 
methodologies that can predict effective combinatorial therapy and guide the design of 
specific treatment strategy in individual patients have been lacking. To bridge this gap, 
we aimed to construct the first kinetic model of the core BCR signaling network and 
use this model to investigate targeted therapy against BCR signaling. We showed that 
simulations with the signaling model reconstructed dynamics of normal B cell signaling 
in silico. Combining the signaling model with a data-trained tumor growth model 
successfully predicted viability response of multiple drug combinations, and identified 
novel synergistic drug combinations such as LYN and SYK inhibitor. 
 
As one of the most important signaling event in B cells, antigen triggered BCR 
activation has been intensively studied during the past decades. Detailed molecular 
interactions in the key signal transduction pathway as well as regulatory feedback loops 
were experimentally identified, providing a unique opportunity to establish a detailed 
kinetic model of the BCR signaling network. Prompted by the rich information available 
in literature, we attempted to establish the first kinetic model to quantitatively 
characterize BCR signaling in silico. The model is able to reproduce major kinetic 
features of BCR signaling observed in experiments. However, we note that 
simplifications and assumptions in the model may call for further improvements. First 
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of all, how antigen recognition leads to proximal BCR activation, namely 
phosphorylation of BCR ITAM motif, LYN and SYK, was not addressed in the model. 
Integration of proximal BCR signaling with downstream signaling model characterized 
here can potentially provide a more comprehensive understanding of how different 
strengths of antigen stimulus might lead to various downstream effector activation and 
distinct cell fate decision. Critically, a negative feedback loop between downstream 
Ca2+ response and upstream phosphatase activity mediated by reactive oxygen species 
(ROS) may play an important role in determining the threshold and amplitude of BCR 
response(65). Furthermore, we did not account for transcriptional regulation of key 
elements in the BCR signaling network that may influence long term signaling response. 
Expression of BLNK, CD79A, SYK, BTK, and CD19 is transcriptionally repressed by 
BLIMP-1, which is activated during germinal center to plasma B cell differentiation 
triggered by BCR activation(66). Additionally, chemical inhibition of SYK was shown 
to induce compensatory upregulation of SYK expression mediated by FOXO1(6). Thus, 
these transcriptional feedbacks that attempt to upregulate expression of components in 
the BCR signaling network upon signaling attenuation may mediate resistance to BCR-
targeted therapy to some extent.  
 
Oncogenic activation of intracellular signaling pathways drives tumor survival and 
proliferation by engaging regulators that antagonize apoptosis or drive cell cycle 
progression.  In the BCR signaling network, NFkB transcribes anti-apoptotic factors 
such as BCL2 and BCR-xL(67) and cell cycle regulators such as cyclin D2(68). 
Conversely, AKT and ERK indirectly repress pro-apoptotic factors, e.g., BIM and BAD 
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as well as negative regulators of CDKs such as p27kip1 and p21cip1(69, 70).  A 
mechanistic characterization of how NFkB, AKT and ERK signal influences tumor 
survival and proliferation requires deep quantitative knowledge of apoptosis and cell 
cycle regulation. In this model, we addressed this question by parameterizing a 
phenotypic tumor growth model from drug response data in TMD8. This 
parameterization revealed TMD8 to be primarily dependent on NFkB signaling. Under 
this condition, dual inhibition of IKK and MALT1, two major kinases in the 
downstream of NFkB signaling cascade, was predicted to have highest growth 
inhibition efficacy. However, we note that the dependency of various survival and 
proliferation signals may vary from patient to patient and even dynamically evolve as 
tumors develop. Indeed, some GCB subtype DLBCL cell lines have been shown to be 
more sensitive to AKT and ERK inhibition than ABC DLBCLs(71, 72). When one 
pathway is blocked by targeted therapy, tumors may adapt by utilizing alternative 
pathways that remain constitutively active. Consequently, simultaneous repression of 
all oncogenic pathways, e.g., through dual inhibition of BTK and PI3K, or sequential 
administration of agents targeting various pathways may ensure more durable response. 
Monitoring tumor growth and probing signaling dependency for longer periods would 
help establish mathematical models that can optimize for long-term benefits. 
 
 
The clinical application of targeted therapy is frequently challenged by highly variable 
drug response among cancer patients. Heterogeneous response to BCR signaling-
targeted therapy was observed in ABC DLBCL cell lines(59) and in clinical trials of 
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ABC DLBCL patients(10). This is likely due to differential expression of proteins in 
the BCR signaling pathway that impact pathway activities in individual patient. In our 
present study, signal transduction is explicitly modeled on the molecular level, which 
provides a straightforward framework to incorporate protein level variation to develop 
patient-specific predictive models. Specifically, expression levels of proteins within the 
BCR signaling network can be measured experimentally using protein expression 
profiling techniques such as Reverse Phase Protein Array (RPPA) or other approaches. 
Then protein expression changes in patients relative to cell line can be incorporated into 
the model to predict optimal treatment strategy for individual patients. We believe that 
the use of patient-specific predictive models can greatly improve the performance of 
targeted therapy in cancer.  
 
We note that besides DLBCL, aberrant BCR signaling was shown to play a role in other 
B cell malignancies such as chronic lymphocytic leukemia (CLL)(73) and mantle cell 
lymphoma(MCL)(74). In Phase II studies of BTK inhibitor Ibrutinib, 71% and 68% 
overall response rate (ORR) was reported in CLL and MCL patients respectively, 
suggesting targeting BCR signaling as promising treatment strategy. Correspondingly, 
the overall framework and predictions reported in this work may also be useful to 
identify drug combinations for CLL and MCL targeted treatment.  
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With a number of advantages of RNA-Seq technology over microarray, i.e. the ability 
to discover novel transcripts, RNA-Seq technology is increasingly used for gene 
expression profiling in cancer studies. While the importance of gene expression based 
stratification of DLBCL subtypes is widely appreciated, all published methods are based 
on microarray platform and application to RNA-Seq data is lacking. To bridge this gap, 
we adapted the original Bayesian classifier method(4) and demonstrate generalizability 
to RNA-Seq data upon log transformation of z score standardization of both training 
and to-be-classified data.  By randomly equally splitting the pre-labeled microarray 
dataset into a training and validation set, we demonstrated that our method performed 
well on the original microarray dataset.  Furthermore, we applied our method to a 
primary DLBCL RNA-Seq dataset. While our classification of ABC and GCB subtypes 
showed good consistency with the hierarchical clustering result of Lymph2Cx 20 gene 
signature, it matched poorly with IHC labels.  However, we further demonstrated that 
the RNA-Seq based ABC/GCB stratification significantly outperformed the IHC label 
in stratifying two subgroups with distinct probability of survival.  
 
A key step in generalizing the classification method to RNA-Seq data is to perform z-
score normalization on both training and to-be-classified data.  This step puts the 
training microarray dataset and the to-be-classified RNA-Seq data on the same scale.  
However it is important to note that we now utilize the relative expression across 
samples as input for classification instead of absolute expression values.  In other words, 
we leverage the fact that within a clinical cohort of DLBCLs there would naturally be a 
subset of ABCs and a subset of GCBs, and the relative gene expression differences 
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between the ABC and GCB subsets should be able to stratify between these two groups.  
A concomitant issue is that when the to-be-classified dataset has very small number of 
samples, the classification can become inaccurate as the samples are likely to be highly 
unevenly distributed between ABC and GCB, i.e. all be ABCs or GCBs. In this case to 
increase classification accuracy it would be important to put the few to-be-classified 
cases with other available DLBCL samples to form a larger cohort and to perform 
classification once on this larger cohort.   
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